Transatlantique Private Wealth LLC Takes $443,000 Position in Enovis Co. (NYSE:ENOV)

Transatlantique Private Wealth LLC bought a new position in shares of Enovis Co. (NYSE:ENOV) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 9,791 shares of the company’s stock, valued at approximately $443,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC boosted its holdings in shares of Enovis by 19.9% during the 1st quarter. GAMMA Investing LLC now owns 1,085 shares of the company’s stock valued at $68,000 after purchasing an additional 180 shares during the last quarter. Treasurer of the State of North Carolina boosted its stake in Enovis by 1.0% during the fourth quarter. Treasurer of the State of North Carolina now owns 23,252 shares of the company’s stock valued at $1,303,000 after buying an additional 220 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in Enovis by 5.4% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 5,185 shares of the company’s stock valued at $290,000 after buying an additional 264 shares during the last quarter. State of Michigan Retirement System grew its holdings in Enovis by 2.5% during the 1st quarter. State of Michigan Retirement System now owns 12,202 shares of the company’s stock valued at $762,000 after buying an additional 300 shares in the last quarter. Finally, Swiss National Bank increased its stake in Enovis by 0.3% in the 1st quarter. Swiss National Bank now owns 97,000 shares of the company’s stock worth $6,058,000 after acquiring an additional 300 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

ENOV has been the subject of a number of research reports. JPMorgan Chase & Co. lowered their target price on Enovis from $53.00 to $50.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Needham & Company LLC dropped their price objective on shares of Enovis from $82.00 to $65.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Finally, Evercore ISI reduced their target price on shares of Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $69.13.

Enovis Price Performance

Shares of ENOV stock opened at $43.65 on Friday. The stock has a 50 day moving average price of $44.73 and a 200 day moving average price of $50.05. Enovis Co. has a 52-week low of $39.98 and a 52-week high of $65.03. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.08 and a current ratio of 2.26. The firm has a market capitalization of $2.39 billion, a P/E ratio of -29.10 and a beta of 1.92.

Enovis (NYSE:ENOV) last released its earnings results on Wednesday, August 7th. The company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.03. The business had revenue of $525.20 million during the quarter, compared to the consensus estimate of $525.99 million. Enovis had a positive return on equity of 4.06% and a negative net margin of 4.73%. The business’s revenue for the quarter was up 22.6% compared to the same quarter last year. During the same period last year, the company earned $0.61 earnings per share. As a group, sell-side analysts predict that Enovis Co. will post 2.7 earnings per share for the current year.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.